Drugs / TAILФR Phage Cocktail
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06559618 | Feb 2025 → Sep 2027 expected | bacteriuria, escherichia coli infection, spinal cord injury | Barbara Trautner | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAILФR Phage Cocktail | “The name of the active treatment IP is TAILФR Phage Cocktail (TPC).” NCT06559618 ↗ |
| Known as | TPC | “The name of the active treatment IP is TAILФR Phage Cocktail (TPC).” NCT06559618 ↗ |
| Modality | Other / unclassified | “investigational phage therapy (IP)” NCT06559618 ↗ |
| Route | Other | “will be administered intravesicularly twice a day” NCT06559618 ↗ |